# ProPhase Labs, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/ProPhase Labs, Inc.). ## Overview ProPhase Labs, Inc. is a U.S.-based life sciences and consumer health company with operations spanning diagnostic services, personal genomics, and branded dietary supplements. Through subsidiaries including ProPhase Diagnostics and Nebula Genomics, it combines laboratory testing, DNA sequencing, and consumer wellness products under one corporate structure. ## Products & services • Personal genomics and DNA sequencing services • Diagnostic testing services • TK Supplements® dietary supplements • Legendz XL® sexual health supplement • Triple Edge XL® energy and stamina supplement • Licensing and development of drug and diagnostic assets - **Personal genomics** (35%) — Consumer DNA sequencing and genetic testing services offered through Nebula Genomics and DNA Complete. - **Diagnostic services** (25%) — Laboratory testing services, including COVID-19 and other molecular diagnostics. - **Consumer products** (30%) — Branded OTC health and dietary supplement products sold under the TK Supplements line. - **Licensing and development** (10%) — Development and commercialization of novel drugs, compounds, diagnostics, and related IP. - Personal genomics and DNA sequencing services - Diagnostic testing services - TK Supplements® dietary supplements - Legendz XL® sexual health supplement - Triple Edge XL® energy and stamina supplement - Licensing and development of drug and diagnostic assets ## Customers The company sells primarily to consumers seeking genetic insights, health information, and wellness products, with Nebula and DNA Complete serving the personal genomics market. It also serves patients, physicians, and payors through diagnostic testing activities, while TK Supplements targets retail consumers buying OTC health and vitality products. - **Personal genomics consumers** (primary) — Buy DNA sequencing and genetic testing for ancestry, health risk, and trait insights. - **Diagnostic testing customers** (primary) — Buy laboratory testing services, historically including COVID-19 and molecular diagnostics. - **Supplement consumers** (secondary) — Buy TK Supplements products for energy, sexual vitality, and general wellness. - **Licensing and development counterparties** (emerging) — Partners or license holders involved in drug, compound, and diagnostic commercialization. - Consumers buying DNA testing for ancestry, health, and genetic insights - Consumers purchasing supplements for energy, vitality, and sexual health - Patients and providers using laboratory diagnostic testing services - Insurance-related counterparties tied to diagnostic reimbursement claims - Retail and online buyers of branded consumer health products ## Geography ProPhase Labs is headquartered in the United States and its operating footprint is centered there, including laboratory space in New Jersey and consumer-facing activities in the U.S. The company also describes Nebula Genomics as a personal genomics business with a broader market reach, but the disclosed operating base and core revenue exposure remain U.S.-centric. - Headquartered in the United States - Laboratory operations have been based in New Jersey - Consumer genomics and supplements are primarily U.S.-focused - Licensing and product development are managed from the U.S. - No country-level revenue disclosure was provided in the excerpts ## Strategy The company is focused on building and commercializing multiple health-related businesses, including genomics, diagnostics, supplements, and licensed product candidates. Its strategy also includes exploring new product technologies and financing growth through equity, debt, collaborations, or other sources as needed. - **Grow personal genomics and consumer health offerings** (medium-term) — These businesses provide recurring consumer-facing revenue opportunities and brand-building potential. - **Commercialize licensed and developed assets** (medium-term) — Drug, compound, and diagnostic development can create higher-value future revenue streams if successful. - **Maintain access to capital** (short-term) — The business mix includes development-stage activities that require funding before they can scale. - Expand personal genomics and consumer DNA testing - Develop and commercialize new drug and diagnostic assets - Support branded supplement sales through TK Supplements - Pursue licensing opportunities for compounds and diagnostics - Use external financing and ATM capacity to fund growth ## Risks The company faces execution risk across several businesses, including consumer complaints, sequencing delays, reimbursement disputes, and the challenge of replacing diagnostic revenue with other lines. It also carries development-stage, financing, and litigation risk, while any digital-asset activity could add volatility and operational complexity. - **Consumer complaints and reputational damage** [high] — DNA testing customers rely on trust, timely results, and data handling quality. - **Sequencing and fulfillment delays** [high] — A change in sequencing lab can delay results and increase service backlogs. - **Insurance reimbursement and collections risk** [critical] — Diagnostic revenue depends on payor reimbursement and timely claim collection. - **Financing and liquidity dependence** [high] — Development and commercialization activities require external capital before scale. - **Litigation and privacy exposure** [medium] — Genetic data handling can trigger privacy claims and regulatory scrutiny. - **Digital asset volatility** [medium] — Any crypto treasury activity can create mark-to-market and custody risk. - Consumer complaints can damage trust in DNA testing and genomics brands - Sequencing delays can disrupt fulfillment and customer satisfaction - Diagnostic reimbursement disputes can impair cash collection - Development-stage businesses may require ongoing external capital - Crypto-related activities could increase volatility and operational risk ## Accounting Investors should watch revenue recognition across diagnostics, genomics, and consumer products because each business may recognize revenue at different points in the customer journey. The company also relies on estimates for accrued expenses, stock-based compensation, contingent liabilities, and collectability of receivables, while litigation and reimbursement disputes can affect provisions and asset recoverability. - **Revenue recognition by business line** — Affects quarterly comparability and reported growth across segments - **Accounts receivable and claim recoverability** — Can materially affect cash flow and bad debt expense - **Contingent liabilities and legal reserves** — Can affect expenses, liabilities, and uncertainty disclosures - **Stock-based compensation** — Impacts operating expenses and dilution analysis - **Asset impairment and valuation** — Can create non-cash charges if expected cash flows weaken - Revenue timing differs across diagnostics, genomics, and product sales - Receivables collectability is important for diagnostic claim recovery - Accrued expenses and contingencies can move with litigation and claims - Stock-based compensation affects operating expense estimates - Impairment or valuation issues may arise for acquired or developed assets --- *Last updated: 2026-04-29T04:49:42.627796+00:00*